Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.2290
-0.2641 (-53.56%)
At close: Nov 20, 2026, 4:00 PM EST
0.2342
+0.0052 (2.27%)
After-hours: Nov 20, 2026, 7:50 PM EST
Aprea Therapeutics Revenue
Aprea Therapeutics had revenue of $3.34K in the twelve months ending September 30, 2026, down -99.32% year-over-year. In the year 2025, Aprea Therapeutics had annual revenue of $285.76K, down -80.98%. That makes Aprea Therapeutics the 47,553rd largest company in the world by revenue and 7,256th in the United States.
Revenue (ttm)
$3.34K
Revenue Growth
-99.32%
P/S Ratio
973.86
Revenue / Employee
$417
Employees
8
Market Cap
3.25M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 285.76K | -1.22M | -80.98% |
| Dec 31, 2024 | 1.50M | 919.35K | 157.63% |
| Dec 31, 2023 | 583.23K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 2.96M |
| Traws Pharma | 2.73M |
| Silo Pharma | 36.05K |
| Azitra | 7.50K |
| Creative Medical Technology Holdings | 3.00K |
APRE News
- 1 day ago - Aprea Therapeutics announces interim results from ACESOT-1051 trial of APR-1051 - TheFly
- 1 day ago - Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona - GlobeNewsWire
- 12 days ago - Aprea Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 16 days ago - Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference - GlobeNewsWire
- 17 days ago - Aprea Therapeutics reports Q3 EPS (9c), consensus (8c) - TheFly
- 17 days ago - Aprea Therapeutics Announces Third Quarter 2026 Financial Results - GlobeNewsWire
- 17 days ago - Aprea Therapeutics Earnings release: Q3 2026 - Filings
- 17 days ago - Aprea Therapeutics Quarterly report: Q3 2026 - Filings